Please login to the form below

Not currently logged in
Email:
Password:

Acorda Therapeutics appoints chief medical officer

Interim CMO Dr Burkhard Blank takes on the post in a permanent capacity

New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer.

Dr Blank has served in the role in a temporary capacity since January this year and now takes on the post permanently.

He brings over 25 years of industry experience to Acorda, and has held senior leadership positions at Altus Pharmaceuticals, Herantis Pharma and Laurantis Pharma.

Prior to this, Dr Blank worked at Boehringer Ingelheim, first as its global head for regulatory affairs before serving as its chief medical officer between 2001 and 2006.

Dr Ron Cohen, president and chief executive of Acorda, said: “I am delighted that Burkhard has joined Acorda as our chief medical officer.

“Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs. This will benefit Acorda's entire pipeline, including our late-stage development programs, CVT-301 and tozadenant for Parkinson's disease.”

5th July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics